News & Videos - SANA BIOTECHNOLOGY INC.

Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome autoimmune and allogeneic immune recognition, function, and persist with stable C-peptide production post-transplant Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases and VIVID trial for SC262 in relapsed/refractory B-cell...

SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the Cowen 45 th Annual Health Care Conference at 3:10 p.m. ET on Monday, March 3, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of...

SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43 rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Wednesday, January 15, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor...

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes Function and Persistence of Pancreatic Islets Were Detectable by Production of Consistent Levels of Circulating...

Fast Track designation is designed to expedite clinical development and regulatory review timelines Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including systemic lupus erythematosus; expect to report initial clinical data in 2025 SEATTLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that the U.S. Food and Drug Administration...

SEATTLE, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. Sana will participate on a panel at Citi’s 2024 Global Healthcare Conference at 2:30 p.m. ET on Tuesday,...

Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology Enrolling patients in the investigator-sponsored trial with hypoimmune-modified primary islet cells, GLEAM trial for SC291 in B-cell mediated autoimmune diseases, and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect data from these studies in 2024 and/or 2025 Announced increased focus on type 1 diabetes and B-cell mediated...

Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform for generating in vivo CAR T cells Modified strategy extends expected cash runway into 2026 with potential for multiple data readouts in 2024 and 2025 SEATTLE, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through...

SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its panel at the Goldman Sachs Cell Therapy Day Conference at 1:00 p.m. ET on Tuesday, October 1, 2024. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of...

SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in September. The presentations will feature a business overview and update. Sana will present at the Morgan Stanley 22 nd Annual Global Healthcare Conference at 11:30 a.m. ET on Wednesday, September 4, 2024. Sana will present at the 2024 Wells...

SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer. “We are thrilled to welcome Dhaval to Sana’s senior leadership team and look forward to partnering with him to build the company, maximize the value of our current pipeline, and secure our long-term future,”...

Continue to advance hypoimmune technology in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases; expect to report initial clinical data in 2024 Enrolling patients in two oncology trials – ARDENT for SC291 in B-cell malignancies and VIVID for SC262 in relapsed/refractory B-cell malignancies; expect to report additional clinical data in 2024 Enrolling...

Healthy transplanted human glial cells replaced diseased glial cells in the brains of human glial chimeric Huntingtin mice Additional proof-of-concept for the advancement of SC379, Sana’s pluripotent stem cell-derived glial progenitor cell product candidate SEATTLE, May 21, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today highlighted that Nature Biotechnology has published a paper titled...

Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Ongoing ARDENT trial for SC291 continues in B-cell malignancies; expect to report additional data in 2024 Enrolling patients in the ongoing GLEAM trial for SC291 in B-cell mediated autoimmune diseases; expect to report initial clinical data in 2024 Enrolling patients in the ongoing VIVID trial for SC262 in relapsed/refractory B-cell malignancies;...

SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in May and June. The presentations will feature a business overview and update. Sana will present at the Citizens JMP Securities Life Sciences Conference at 11:30 a.m. ET on Monday, May 13, 2024. Sana will present at the BofA Securities 2024...

Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory NHL and CLL suggest ability to dose safely, demonstrate the desired immune evasion profile, and early clinical efficacy using hypoimmune technology Announced SC291 IND clearance for B-cell mediated autoimmune diseases with goal to report initial clinical data in 2024 Announced SC262 IND...

SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the Cowen 44 th Annual Health Care Conference at 2:50 p.m. ET on Wednesday, March 6, 2024. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page...

Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence without immunosuppression for six month study duration Administration of anti-CD47 antibody after six months demonstrated the principle of graft ablation and a potential safety strategy SEATTLE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the...

SEATTLE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has closed its underwritten upsized public offering of 21,772,728 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 4,500,000 additional shares of its common stock, at a price to the public of $5.50 per share and, in lieu of common stock to certain...

SEATTLE, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has priced its underwritten upsized public offering of 17,272,728 shares of its common stock at a price to the public of $5.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 12,727,272 shares of common stock at a price to the public of $5.4999 per pre-funded...